W
William H. Yang
Researcher at University of Ottawa
Publications - 69
Citations - 3236
William H. Yang is an academic researcher from University of Ottawa. The author has contributed to research in topics: Hereditary angioedema & Angioedema. The author has an hindex of 23, co-authored 61 publications receiving 2529 citations.
Papers
More filters
Journal ArticleDOI
Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema
Marco Cicardi,Aleena Banerji,F. Bracho,Alejandro Malbrán,Bernd Rosenkranz,Marc A. Riedl,Konrad Bork,William R. Lumry,Werner Aberer,Henning Bier,Murat Bas,Jens Greve,Thomas K. Hoffmann,Henriette Farkas,Avner Reshef,Bruce Ritchie,William H. Yang,Jürgen Grabbe,Shmuel Kivity,Wolfhart Kreuz,Robyn J. Levy,Thomas A. Luger,Krystyna Obtułowicz,Peter Schmid-Grendelmeier,Christian Bull,Brigita Sitkauskiene,William B Smith,Elias Toubi,Sonja Werner,Suresh Anné,Janne Björkander,Laurence Bouillet,Enrico Cillari,D. Hurewitz,Kraig W. Jacobson,Constance H. Katelaris,Marcus Maurer,Hans F. Merk,Jonathan A. Bernstein,Conleth Feighery,Bernard Floccard,Gerald J. Gleich,Jacques Hébert,Martin Kaatz,Paul K. Keith,Charles H. Kirkpatrick,David Langton,Ludovic Martin,Christiane Pichler,David Resnick,Duane Wombolt,Diego S. Fernández Romero,Andrea Zanichelli,Francesco Arcoleo,Jochen Knolle,Irina Kravec,Liying Dong,Jens Zimmermann,Kimberly Rosen,Wing Tze Fan +59 more
TL;DR: In patients with hereditary angioedema having acute attacks, a significant benefit of icatibant as compared with tranexamic acid in one trial and a nonsignificantbenefit of ic atibant in the other trial are found with regard to the primary end point.
Journal ArticleDOI
AR101 Oral Immunotherapy for Peanut Allergy
Brian P. Vickery,Andrea Vereda,Thomas B. Casale,Kirsten Beyer,George Du Toit,Jonathan O'b Hourihane,Stacie M. Jones,Stacie M. Jones,Wayne G. Shreffler,Annette Marcantonio,Rezi Zawadzki,Lawrence Sher,W. Carr,Stanley Fineman,Leon Greos,Rima Rachid,M Dolores Ibáñez,Stephen A. Tilles,Amal Assa'ad,Caroline Nilsson,Ned Rupp,Michael J Welch,Gordon Sussman,Sharon Chinthrajah,Katharina Blumchen,Ellen Sher,Jonathan M. Spergel,Frederick E Leickly,Stefan Zielen,Julie Wang,Georgiana M Sanders,Robert A. Wood,Amarjit Cheema,Carsten Bindslev-Jensen,Stephanie A. Leonard,Rita Kachru,Douglas T Johnston,Frank C Hampel,Edwin H. Kim,Aikaterini Anagnostou,Jacqueline A. Pongracic,Moshe Ben-Shoshan,Hemant P Sharma,Allan Stillerman,Hugh H Windom,William H. Yang,Antonella Muraro,José Manuel Zubeldia,Vibha Sharma,Morna J. Dorsey,Hey Chong,Jason A. Ohayon,J. Andrew Bird,Tara F. Carr,Dareen Siri,Montserrat Fernandez-Rivas,David K Jeong,David Fleischer,Jay A. Lieberman,Anthony E.J. Dubois,Marina Tsoumani,Christina E. Ciaccio,Jay M. Portnoy,Lyndon E Mansfield,Stephen B Fritz,Bruce J. Lanser,Jonathan Matz,Hanneke N G Oude Elberink,Pooja Varshney,Stephen G Dilly,Daniel C. Adelman,A. Wesley Burks +71 more
TL;DR: Treatment with AR101 resulted in higher doses of peanut protein that could be ingested without dose‐limiting symptoms and in lower symptom severity during peanut exposure at the exit food challenge than placebo, in this phase 3 trial of oral immunotherapy in children and adolescents who were highly allergic to peanut.
Journal ArticleDOI
Hereditary angiodema: a current state-of-the-art review, VII: Canadian Hungarian 2007 International Consensus Algorithm for the Diagnosis, Therapy, and Management of Hereditary Angioedema
Tom Bowen,Marco Cicardi,Konrad Bork,Bruce L. Zuraw,Michael M. Frank,Bruce Ritchie,Henriette Farkas,Lilian Varga,Lorenza C. Zingale,Karen Binkley,Eric Wagner,Peggy Adomaitis,Kristylea Brosz,Jeanne Burnham,Richard Warrington,Chrystyna Kalicinsky,Sean R. Mace,Christine McCusker,R. Robert Schellenberg,Lucia Celeste,Jacques Hébert,Karen A. Valentine,Man-Chiu Poon,Bazir Serushago,Doris Neurath,William H. Yang,Gina Lacuesta,Andrew C. Issekutz,Azza Hamed,Palinder Kamra,John M. Dean,Amin Kanani,Donald Stark,Georges-Etienne Rivard,Eric Leith,Ellie Tsai,Susan Waserman,Paul K. Keith,David Page,Silvia Marchesin,Hilary Longhurst,Wolfhart Kreuz,E. Rusicke,Inmaculada Martinez-Saguer,Emel Aygören-Pürsün,George Harmat,George Füst,Henry Li,Laurence Bouillet,Teresa Caballero,Dumitru Moldovan,Peter J. Späth,Sara Smith-Foltz,István Nagy,Erik Waage Nielsen,Christoph Bucher,Patrik Nordenfelt,Zhi Yu Xiang +57 more
TL;DR: There is a paucity of double-blind, placebo-controlled trials on the treatment of HAE, making levels of evidence to support the algorithm less than optimal.
Journal ArticleDOI
Effect of Epicutaneous Immunotherapy vs Placebo on Reaction to Peanut Protein Ingestion among Children with Peanut Allergy: The PEPITES Randomized Clinical Trial
David Fleischer,Matthew Greenhawt,Gordon Sussman,Philippe Bégin,Anna Nowak-Wegrzyn,Daniel Petroni,Kirsten Beyer,Terri F. Brown-Whitehorn,Jacques Hébert,Jonathan O'b Hourihane,Dianne E. Campbell,Stephanie A. Leonard,R. Sharon Chinthrajah,Jacqueline A. Pongracic,Stacie M. Jones,Lars Lange,Hey Chong,Todd D. Green,Todd D. Green,Robert J. Wood,Amarjit Cheema,Susan L. Prescott,Pete Smith,William H. Yang,Edmond S. Chan,Aideen Byrne,Amal Assa'ad,J. Andrew Bird,Edwin H. Kim,Lynda C. Schneider,Carla M. Davis,Bruce J. Lanser,Romain Lambert,Wayne G. Shreffler +33 more
TL;DR: Among peanut-allergic children aged 4 to 11 years, the percentage difference in responders at 12 months with the 250-&mgr;g peanut-patch therapy vs placebo was 21.7% and was statistically significant, but did not meet the prespecified lower bound of the confidence interval criterion for a positive trial result.
Journal ArticleDOI
The monosodium glutamate symptom complex: Assessment in a double-blind, placebo-controlled, randomized study
TL;DR: Oral challenge with MSG reproduced symptoms in alleged sensitive persons, and mechanism of the reaction remains unknown, but symptom characteristics do not support an IgE-mediated mechanism.